DCPH
Deciphera Pharmaceuticals LLCNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$2.21B
P/E Ratio
—
EPS
$-2.21
Beta
0.18
52W High
$0.00
52W Low
$0.00
50-Day MA
$21.67
200-Day MA
$15.94
Dividend Yield
—
Profit Margin
-108.90%
Forward P/E
—
PEG Ratio
—
About Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $174.91M |
| Gross Profit (TTM) | $-62.55M |
| EBITDA | $-204.61M |
| Operating Margin | -108.50% |
| Return on Equity | -50.40% |
| Return on Assets | -26.60% |
| Revenue/Share (TTM) | $2.03 |
| Book Value | $3.85 |
| Price-to-Book | 7.00 |
| Price-to-Sales (TTM) | 12.65 |
| EV/Revenue | 11.24 |
| EV/EBITDA | -4.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.50% |
| Shares Outstanding | $86.48M |
| Float | $46.43M |
| % Insiders | 28.48% |
| % Institutions | 72.03% |
Historical Volatility
HV 10-Day
0.00%
HV 20-Day
0.00%
HV 30-Day
0.00%
HV 60-Day
0.00%
HV Rank
—
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DCPH and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026